Medical Device Import Permit Categories in Mexico: Eight Routes and Planning

1. Key takeaways

Mexican import permits are differentiated by the status and intended use of the device. In practice they are usually handled under eight categories: devices already holding a health registration (the most common case), third-party manufacturing, personal use, professional use, clinical research, donations, used devices, and laboratory testing. The permit is applied for batch by batch, and its validity is tied to the approved quantity: it expires whichever comes first, when the quantity is used up or when the term ends. Because both constraints bind simultaneously, batch planning has to respect the calendar and the volume at the same time, and a permit that looks comfortable on one dimension can still fail on the other. Selecting the right category before assembling the dossier is the step that most often determines whether the application is accepted or returned. It is worth treating category selection as a formal decision with a recorded rationale rather than an assumption inherited from a previous shipment.

• Eight practical categories cover import permits, from registration-backed commercial imports through clinical research and laboratory testing.
• The category determines the document checklist, so the category must be fixed before materials are prepared.
• Permit validity is constrained by both the term and the approved quantity, whichever expires first.
• Annex II of the 2025 agreement lists 104 low-risk devices exempt from the import permit, replaced by a port declaration.
• Devices containing radioactive sources require an additional CNSNS permit beyond the ordinary import permit.

2. Legal basis

The import permit system draws on the medical inputs regulation as amended in 2026, operates through the foreign trade single window, and is modified at the margins by the 2025 low-risk agreement and the special regime for radioactive sources. The table below consolidates the four reference points.

3. Expert insights

Insight one: the category determines the document checklist. The registration-backed category serves batch commercial distribution; third-party manufacturing corresponds to assembly or manufacturing under IMMEX; personal use requires a valid prescription; professional use targets a specific physician and requires evidence that no comparable technology is available domestically; clinical research requires a study protocol approved by COFEPRIS; donations require confirmation from the receiving institution that the goods will not be sold; used devices require an invoice and confirmation of functionality; and laboratory testing covers trials that do not involve human subjects. Preparing documents before fixing the category is the most common self-inflicted rework in this area, because materials assembled for one category rarely transfer cleanly to another.

Insight two: validity and quantity bind together. The permit expires at whichever comes first of the validity term and the approved quantity. Batch planning must therefore consider both the time window and the quantity ceiling. A shipment plan that respects the calendar but exhausts the approved units, or the reverse, will strand goods on one side of the border, so the two constraints should be tracked in the same ledger.

Insight three: the clinical research category is paired with the research route. The clinical research import permit requires an approved study protocol and is linked with the clinical trial authorisation process on DIGIPRiS. The two approvals are separate procedures, but their sequencing matters: the protocol must be approved before the import application is filed, so the research timeline and the import timeline need to be built as one integrated plan.

Insight four: Annex II has changed the import cost profile for some categories. The 104 low-risk devices listed in Annex II are exempt from the import permit and move instead to a port declaration. For these products the administrative cost of the import step drops significantly, but the GMP and technical vigilance obligations are retained. The saving is real, yet it is bounded: what disappears is the permit procedure, not the compliance framework behind it. Teams moving products onto this route should update their cost models but keep their quality and vigilance processes exactly where they were.

Insight five: devices with radioactive sources carry an extra permission. Products containing radioactive sources, such as X-ray equipment, need a CNSNS permit in addition to the ordinary import permit, and that lead time must be scheduled separately. Assuming the nuclear-side permission will move in step with the trade-side filing is a planning error that surfaces late, when the equipment is already booked for transport.

4. Practical recommendations

• Determine the import permit category from the intended use of the product first, and prepare the document checklist only after the category is fixed, avoiding returns caused by using the wrong category.
• Maintain a batch ledger recording, for each permit, its validity term, the approved quantity and the quantity already used, so both constraints are visible in one place.
• Link the clinical research category to the protocol approval schedule and do not file the import application before the protocol has been approved.
• For Annex II products, switch to the port declaration process while retaining the GMP and vigilance evidence that supports it.
• Reserve separate lead time for the CNSNS permit for products containing radioactive sources.

5. Verification checklist

• □ The applicable import permit category has been determined
• □ The document checklist has been prepared by category
• □ The batch ledger captures both the validity term and the quantity constraint
• □ The clinical research category is linked to the protocol approval
• □ Annex II products have switched to the port declaration
• □ The CNSNS permit is scheduled for products with radioactive sources

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Mexican market. Our team manages COFEPRIS registrations and equivalence (equivalencia) reviews, coordinates third-party authorised centre routes, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com